Mansa Mbenga

Senior PMDT Consultant Treatment and Care Team Lead

Mansa Mbenga is a medical doctor with 14 years professional experience and is an expert in the management of drug-resistant TB and TB clinical trials.

Mansa has extensive experience in health system innovation, research, capacity building and all aspects of clinical trials, including project design, developing policies and writing operating procedures, implementation and management. Mansa has worked extensively in-country to develop TB programs and training and supporting health care staff in the implementation of good clinical practices. Mansa holds a medical degree, a postgraduate degree in Phthisiology from the People Friendship University of Russia, a Diploma in Tropical Medicine and Hygiene from the Royal College of Physicians in the United Kingdom and a current Good Clinical Practice Certificate.

Within KNCV, Mansa is a Senior Programmatic Management of Drug-Resistant (PMDT) Consultant, Treatment and Care Team Lead, and focal point for children and adolescent TB. Mansa provides global, regional and country level technical assistance on the management of drug-resistant TB, operational research, and the implementation of TB prevention and care programs. Mansa also focuses on programs to train and support health care staff, stimulating innovation and knowledge management.

Recent publications

  1. M Mbenga, H Margaryan, Z Tigay, NN Parpieva, Z Baltesheva, V Khvane, A Baynyasova, B-T Nyang’wa. Setting up the first TB-PRA CTECAL trial site: experience from Uzbekistan. The International Journal of Tuberculosis and Lung Disease, Volume 22, Number 11, November 2018, Supplement 2, pp. 293 – 294. SOA 13-1131-26
  2. Tesema, Z. Gashu, D. Gemechu, Y. Alemayehu, A. Bedru, A. Gebreyohannes,D. Jerene, M. Mbenga, T. Belachew. Impact of COVID-19 on treatment outcomes of drug-resistant tuberculosis in Ethiopia. The International Journal of Tuberculosis and Lung Disease, Volume 26, November 2022, Supplement 2, p.S85. EP-01-606
  3. Toktogonova, V. Mirtskulava, A. Gebhard, F. Waries, M. Mbenga, S. Foraida, B. Myrzaliev, M. Ahmatov, A. Duishekeeva, A. Soorombaeva, A. Kulzhabaeva, K. Sakmamatov. The first cohort of tuberculosis patients on the BPaL regimen under operational research conditions in the Kyrgyz Republic: preliminary results. The International Journal of Tuberculosis and Lung Disease, Volume 26, November 2022, Supplement 2, p.S159. OA15-312-09
  4. Mbenga, A. Slyzkyi, V. Mirtskhulava, S. Pak, A. Gebhard, G. Utepkalieva, A. Sagimbekova, M. Adenov, G. Ryskulov. Decentralization of ECG monitoring using a mobile device (KardiaMobile-6L) for patients on drug-resistant tuberculosis (DR-TB) treatment in an outpatient setting. The International Journal of Tuberculosis and Lung Disease, Volume 26, November 2022, Supplement 2, p.S255. OA24-375-10


read all the KNCV publications

KNCV has been fighting TB since its establishment in 1903. Over the past 120 years, the organization has acquired indispensable knowledge and experience in the field of effective TB prevention and care, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework and integrity
Our patroness
Partner with us


De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.